CASE REPORT
Atypical psychopathology and clinical challenges in treating a patient with HIV-associated neurocognitive disorder
 
More details
Hide details
 
Submission date: 2017-10-22
 
 
Acceptance date: 2018-01-10
 
 
Publication date: 2018-09-25
 
 
HIV & AIDS Review 2018;17(3):224-226
 
KEYWORDS
TOPICS
ABSTRACT
Human immunodeficiency virus (HIV) has been known to be associated with primary central nervous system (CNS) manifestations in form of cognitive, behavioral, and affective symptoms. In the absence of opportunistic infections, the initial diagnosis of HAND (HIV-associated neurocognitive disorder) is difficult to suspect based on above in middle-aged adults, which commonly is misinterpreted as part of psychiatric disorders. Once HIV is diagnosed on serological testing, the personality changes are often colored by cognitive deficits induced by the illness itself, or because of antiretroviral treatment (ART) induced adverse effects, which can interfere with treatment compliance and worsening of HIV status. Acute onset alteration in mental status is known to happen with ART and HIV. With HIV, it can occur either because of primary CNS infection or opportunistic infections, whereas particular medications of ART were known to cause neuro-psychiatric manifestations ranging from anxiety, sleep disturbances, and short-lived increased dreams to psychosis. However, switching into aberrant states of consciousness with intense perceptual alterations for prolonged periods has rarely been reported. This case report highlights the importance of unique psychopathology and clinical helplessness in case of HAND, where cost-benefit of treatment change and psychoeducation of the family was a challenge.
REFERENCES (22)
1.
Allavena C, Le Moal G, Michau C, et al. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir Ther 2006; 11: 263-265.
 
2.
Bonnet F, Amieva H, Marchant F, et al.; S CO3 Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS 2013; 27: 391-400.
 
3.
Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30: 237-246.
 
4.
Foster R, Olajide D, Everall IP. Antiretroviral therapy-induced psychosis: case report and a brief review of the literature. HIV Med 2003; 4: 139-144.
 
5.
Hinsch MC, Reichelt D, Husstedt IW. Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses. Nervenarzt 2014; 85: 1304-1308.
 
6.
Jayarajan N, Chandra PS. HIV and mental health: An overview of research from India. Indian J Psychiatry 2010; 52 (Suppl 1): S269-S273.
 
7.
Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011; 15: 1803-1818.
 
8.
Kumar P, Jain MK. Progressive multifocal leukoencephalopathy in AIDS camouflaged with catatonia: A wolf in sheep’s clothing. Indian J Psychiatry 2006; 48: 69-71.
 
9.
Küper M, Rabe K, Esser S, et al. Structural gray and white matter changes in patients with HIV. J Neurol 2011; 258: 1066-1075.
 
10.
De la Garza LC, Paoletti-Duarte S, García-Martín C, Gutiérrez- Casares JR. Efavirenz-induced psychosis. AIDS 2001; 15: 1911-1912.
 
11.
Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis 2007; 45: e128-130.
 
12.
Manning TG. Efavirenz and psychosis: is there a link? Aust NZJ Psychiatry 2012; 46: 687-688.
 
13.
Nebhinani N, Mattoo SK. Psychotic Disorders with HIV Infection: A Review. German J Psychiatry 2013; 16: 43-48.
 
14.
Nedelcovych MT, Manning AA, Semenova S, et al. The Psychiatric Impact of HIV. ACS Chem Neurosci 2017; 8: 1432–1434.
 
15.
Neuropsychiatric aspects of HIV infection among older adults. Bull World Health Organ 1990; 68: 671-681.
 
16.
Oudijn MS, Vrijlandt CM, Casteelen G. Severe psychosis in an African woman due to the antiretroviral agent efavirenz. Ned Tijdschr Geneeskd 2006; 150: 643-644.
 
17.
Poulsen HD, Lublin HK. Efavirenz-induced psychosis leading to involuntary detention. AIDS 2003; 17: 451-453.
 
18.
Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology 2012; 79: 2328-2334.
 
19.
Steinbrink F, Evers S, Buerke B, et al. German Competence Network HIV/AIDS. Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. Eur J Neurol 2013; 20: 420-428.
 
20.
Sütterlin S, Vögele C, Gauggel S. Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.
 
21.
J Neuropsychiatry Clin Neurosci 2010; 22: 361-369.
 
22.
David A, Fleminger S, Kopelman M, et al. Lishman’s Organic Psychiatry: A Textbook of Neuropsychiatry. 4th ed. http://www.wiley.com/WileyCDA/... (Accessed: 25 August 2017).
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top